TAG:
pathologists
Best Ways to Gather, Access, Report PAMA Price Data to CMS
By Joseph Burns | From the Volume XXVI No. 4 – March 18, 2019 Issue
CEO SUMMARY: All clinical labs required to report their private payer lab test price data are now in the midst of collecting that data. One big change in PAMA reporting is that the federal Centers for Medicare and Medicaid Services now defines most hospital and health system labs as “ap…
Pathologist’s Errors Associated with 12 Deaths at Arkansas VA
By Robert Michel | From the Volume XXVI No. 3 – February 25, 2019 Issue
IN AN UPDATE TO A CASE REPORTED LAST YEAR, the investigation at the Arkansas Veterans Heath Care System of the Ozarks and the Veterans Affairs Medical Center in Fayetteville, Ark., now shows that as many as 12 veterans died as a result of this one pathologist’s err…
Wisconsin Provides Peek at Pathology’s Future
By R. Lewis Dark | From the Volume XXVI No. 3 – February 25, 2019 Issue
BIGGER PATHOLOGY GROUPS AND METROWIDE OR STATEWIDE COVERAGE will be major characteristics in the anatomic pathology profession as healthcare continues to transform in new ways. That is why the reasons for the substantial growth in case volume and revenue at North Shore Pathologists …
Patient Care Focus Helps Path Group Win Contract
By Joseph Burns | From the Volume XXVI No. 3 – February 25, 2019 Issue
CEO SUMMARY: When Ascension Wisconsin wanted one pathology group to serve its needs statewide, North Shore Pathologists responded to the request for proposal by focusing on how pathologists can improve patient care through a patient-centered model. Other pathology groups responded with pr…
Critical Lessons for Labs That Report PAMA Medicare Data
By Mary Van Doren | From the Volume XXVI No. 2 – February 4, 2019 Issue
This is an excerpt from a 1,565-word article in the Feb.4 issue of THE DARK REPORT. The full article is available to paid members of The Dark Intelligence Group. CEO SUMMARY: With most hospitals now included as “applicable laboratories” in the PA…
Useful Lessons for Labs That Report PAMA Data
By Joseph Burns | From the Volume XXVI No. 2 – February 4, 2019 Issue
CEO SUMMARY: Will clinical labs heed the lessons learned from the first PAMA private payer market price reporting cycle that CMS conducted in 2017? One major difference is that the definition of applicable laboratories now includes most hospital labs. This creates the opportunity for a la…
CEO Offers Lab Strategies for a Post-PAMA World
By Joseph Burns | From the Volume XXVI No. 1 – January 14, 2019 Issue
CEO SUMMARY: With so many market forces working against the economic interests of clinical laboratories, it is essential that all labs develop appropriate strategies designed to sustain the quality of laboratory testing services and the financial integrity of the laboratory organization. …
Why PAMA May Be Poised to Disrupt Lab Industry
By Robert Michel | From the Volume XXVI No. 1 – January 14, 2019 Issue
CEO SUMMARY: This will be one of the most challenging years facing the clinical lab industry since the early 1990s, when closed panel HMOs were the disruptive force that generated deep cuts in lab test prices. However, unlike HMOs of that era, the CMS scheme to collect private payer lab t…
Is There a Future for Hospital Lab Outreach Programs?
By Mary Van Doren | From the Volume XXVI No. 1 – January 14, 2019 Issue
CEO SUMMARY: This will be one of the most challenging years facing the clinical lab industry since the early 1990s. The CMS scheme to collect private payer lab test prices and use that data to set Medicare clinical laboratory test pric…
In PAMA Appeal, ACLA Says Federal District Court Erred
By Joseph Burns | From the Volume XXVI No. 1 – January 14, 2019 Issue
LAST MONTH the American Clinical Laboratory Association (ACLA) filed an appeal in its case against the federal Department of Health and Human Services (HHS). In its court filing, the ACLA said that a federal district court judge erred in her ruling against the lab as…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized